Get Adobe Flash player


Аuthors: S. A. Semenchuk

Pages: 863–873



Introduction. Coronary artery disease (CAD) is one of the important causes of cardiovascular morbidity and mortality globally, giving rise to more than 7 million deaths annually. In Ukraine, the number of patients increased by 60 332 person only in 2014.

Of the total cost of CVD in Europe, around 53 % (€ 111 billion) is due to health care costs, 26 % (€ 54 billion) to productivity losses and 21 % (€ 45 billion) to the informal care of people with CVD.

Evidence supports an association between CAD trends with major cardiovascular risk factors. Despite the rapid development of medical educational institutions on healthy lifestyle, the main reasons for the growth of cardiac pathology in Ukraine and abroad are modifiable factors of CVD, such as high blood pressure, diabetes, obesity, metabolic syndrome, abnormal lipids, tobacco use, and physical inactivity.

Comorbidity of chronic liver disease with cardiovascular diseases might be of particular interest to the study of cardiac problems. In this case the pathogenic mechanisms could be started and progress the condition of each disease.

The key links of the pathogenesis of these diseases are atherogenic dyslipidemia, chronic systemic inflammation, endothelial dysfunction and hemodynamic disturbances.

The most common form of chronic liver diseases is nonalcoholic fatty liver disease: its prevalence in different populations reaches 33 %, including among patients with obesity – 90 % of diabetes mellitus 2 type – 60–70 % with metabolic syndrome.

The findings of a literature review noticed the importance of assessing hepato-cardiac risk in patients with comorbidity CAD and liver pathology and optimization of drug therapy that will improve the course and prognosis of each disease.

Purpose. Summarize the data of the modern literature views on issue of risk factors in cardiovascular disease.

Keywords: coronary artery disease, comorbidity, risk factors, atherogenic dyslipidemia, endothelial dysfunction.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text


  1. Akın L. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr. 2013;102:107–113.
  2. Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev. Esp. Enferm. Dig. 2015;107(1):10–6.
  3. Antopol'skaya YeV, Shveynov IA. [Morphological changes in the liver and organs of immunogenesis in cardiovascular diseases]. Kursk Scient. and Pract. Bulletin "The Man and His Health". 2006;4:25–28.
  4. Baharvand-Ahmadi B, Sharifi K, Namdari M. Prevelence of non-alcoholic fatty liver disease on patients with coronary artery disease. ARYA Atheroscler. 2016;12(4):201–205.
  5. Bailey KA, Haj FG, Simon SI, Passerini AG. Atherosusceptible Shear Stress Activates Endoplasmic Reticulum Stress to Promote Endothelial Inflammation. Sci Rep. 2017 Aug 15;7(1):8196. doi: 10.1038/s41598-017-08417-9.
  6. Baumgartner R, Forteza MJ, Ketelhuth DFJ. Enhanced inflammatory response in patients with preinfarction unstable angina. Cytokine. 2017 Sep 9. pii: S1043-4666(17)30259-4. doi: 10.1016/ j.cyto.2017.09.004.
  7. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J. Am. Coll. Cardiol. 2007;49(6):631–42.
  8. Bories GFP, Leitinger N. Macrophage metabolism in atherosclerosis. FEBS Lett. 2017 Aug 10. doi: 10.1002/1873-3468.12786. 
  9. Bueverova EL, Drapkina OM, Ivashkin VT. [Atherogenic dyslipidemia and liver]. Ros. med. News. 2008;13(1):17–23.
  10. Bugianesi E, Gastaldelli A. Hepatic and cardiac steatosis: Are they coupled? Heart Fail. Clin. 2012;8:663–670.
  11. Colak Y, Senated E, Yesil A, et al. Assesment of endothelial disfunction in patients with non-alcoholic fatty liver disease. Endocrine. 2013;.43(1):100–107.
  12. Damnjanović G, Jelić M, Dindić B, Ilić S. [Serum concentration of soluble adhesive molecules in patients with different forms of coronary artery disease]. Vojnosanit Pregl. 2009;66(4):265-70.
  13. Dogru Т, Genc H, Tapan S, et al. Elevated asymmetric dimethylarginine in plasma: An early marker for endothelial dysfunction in non-alcoholic fatty liver disease. Diabetes Research and Clinical Practice. 2012;96(1):47–52.
  14. Drapkina OM, Korneeva ON [Non-alcoholic fatty liver disease and cardiovascular risk: the influence of the female]. Pharmateka. 2010;15:28–33.
  15. Dullaart RP, de Vries R, Sluiter WJ, et al. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2009;70(2):221-6.
  16. Fadeyenko GD, Solomentseva GD, Fadeenko TA, Dovganiuk IE. [Early signs of atherosclerosis in patients with non-alcoholic fatty liver disease]. Modern Gastroenterol. 2014;4(78):32–37.
  17. Feitosa MF, Reiner AP, Wojczynski MK, Graff M, North KE, Carr JJ, Borecki IB. Sex-influenced association of nonalcoholic fatty liver disease with coronary heart disease. Atherosclerosis. 2013;227:420-424.
  18. Ferderbar S, Pereira EC, Apolinário E, et al. Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes Metab Res Rev. 2007;23(1):35–42.
  19. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. doi: 10.1186/1741-7015-11-117.
  20. Hadj Ahmed S, Kaoubaa N, Kharroubi W, Zarrouk A, Najjar MF, Batbout F, Gamra H, Lizard G, Hammami M. Association of plasma fatty acid alteration with the severity of coronary artery disease lesions in Tunisian patients. Lipids Health Dis. 2017 Aug 14;16(1):154. doi: 10.1186/s12944-017-0538-y.
  21. Hala el-Mesallamy H, Suwailem S, Hamdy N. Evaluation of C-reactive protein, endothelin-1, adhesion molecule(s), and lipids as inflammatory markers in type 2 diabetes mellitus patients. Mediators Inflamm. 2007;2007:73635.
  22. Handzyuk VA. [Analysis of the incidence of ischemic heart disease in Ukraine]. Ukr. J. of Cardiol. 2014;3:45-52.
  23. Hansson GK. Inflammation and Atherosclerosis - The End of a Controversy. Circulation. 2017 Sep 15. pii: CIRCULATIONAHA.117.030484. doi: 10.1161/CIRCULATIONAHA.117.030484. 
  24. Huhlina OS, Gorbatyuk IB, Bobyk NV, Syrota CA [Pathogenetic mechanisms and risk factors of interchange of chronic cholecystitis, gallbladder cholesterosis of obesity and coronary heart disease]. Buk. Med. J. 2015;5;2(52):267–271.
  25. Joseph P1, Leong D2, McKee M2, Anand SS2, Schwalm JD2, Teo K2, Mente A2, Yusuf S2. Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res. 2017 Sep 1;121(6):677-694. doi: 10.1161/CIRCRESAHA.117.308903.
  26. Jung JY, Park SK, Ryoo JH, Oh CM, Kang JG, Lee JH, Choi JM. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res. 2017 May;47(6):522–532. doi: 10.1111/hepr.12770. 
  27. Kang HH, Kim IK, Lee HI, Joo H, Lim JU, Lee J, Lee SH, Moon HS. Chronic intermittent hypoxia induces liver fibrosis in mice with diet-induced obesity via TLR4/MyD88/MAPK/NF-kB signaling pathways. Biochem Biophys Res Commun. 2017 Aug 19; 490(2):349–355.
  28. Kolesnikova EV. [Non-alcoholic fatty liver disease and arterial hypertension: what have we achieved in understanding the problem]. Ukr. med. J. 2014;3:61-66.
  29. Kozakova M, Palombo C, Paterni M et al. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology. 2012;55(5):1406–1415.
  30. Kucukazman M, Ata N, Yavuz B, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. Eur. J. of Gastr. and Hepat. 2013;25:147–151.
  31. Kuriata AV, Grechanik MM. [Functional state of vascular endothelium in patients with coronary heart disease in combination with non-alcoholic fatty liver disease depending on body weight and the effect of statin therapy]. Zaporozhye Med. J. 2015;1(88):14–19.
  32. Li X, Xia M, Ma H, et al. Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study. Atherosclerosis. 2012;224:480–485.
  33. Long MT, Pedley A, Massaro JM, Hoffmann U, Fox CS. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS One. 2016 Jun 24;11(6):e0157517. doi: 10.1371/journal.pone.0157517. 
  34. Lyadoshchuk VA, Denisenko AD. [The content of asymmetric dimethylargin in the blood plasma of patients with coronary heart disease]. Med. acad. J. 2011;11(1):30–33.
  35. Mackness B, Hine D, McElduff P, et al. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006;186(2):396-401.
  36. Mak KH, Bhatt DL, Shao M et al. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur. Heart J. 2009;30(7):857–865.
  37. Mangge H, Almer G, Truschnig-Wilders M, et al. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010;17(36):4511–20.
  38. Motamed N, Rabiee B, Poustchi H, Dehestani B, Hemasi GR, Khonsari MR, Maadi M, Saeedian FS, Zamani F. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol. 2017 Feb;41(1):31–38. doi: 10.1016/j.clinre.2016.07.005.
  39. Mozos I, Malainer C, Horbańczuk J, Gug C, Stoian D, Luca CT, Atanasov AG. Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases. Front Immunol. 2017 Aug 31;8:1058. doi: 10.3389/fimmu.2017.01058.
  40. Öztürk H, Gümrükçüoğlu HA, Yaman M. Hepatosteatosis and carotid intima-media thickness in patients with myocardial infarction. J Med Ultrason. 2016;43(1):77-82. doi: 10.1007/s10396-015-0649-x.
  41. Pejkov H, Kedev S, Panov S, Srbinovska-Kostovska E, Lang I. Atherosclerosis of coronary blood vessels - local or systemic inflamation? Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2013;34(3):5–11.
  42. Perera N, Indrakumar J, Abeysinghe W. Non-alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16:37.
  43. [42] Persico M, Masarone M, Damato A, Ambrosio M, Federico A, Rosato V, Bucci T, Carrizzo A, Vecchione C. Non alcoholic fatty liver disease and eNOS dysfunction in humans. BMC Gastroenterol. 2017;17(1):35. doi: 10.1186/s12876-017-0592-y.
  44. Pilely K, Fumagalli S, Rosbjerg A, Genster N, Skjoedt MO, Perego C, Ferrante AMR, De Simoni MG, Garred P. C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques. Front Immunol. 2017 Aug 29;8:1040. doi: 10.3389/fimmu.2017.01040. 
  45. Puchner SB, Lu MT, Mayrhofer T. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015;274(3):693–701. doi: 10.1148/radiol.14140933.
  46. Rafiq N1, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8. doi: 10.1016/j.cgh.2008.11.005
  47. Sakhanda І, Nehoda T, Syatynya M. [Risk factors, the structure and dynamics of development of cardiovascular morbidity in Ukraine]. Drugs of Ukraine. 2015;4(25):116–118.
  48. Santoro N, Caprio S. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Obese Adolescents: A Looming Marker of Cardiac Dysfunction. Hepatology. 2014;59(2):372–374. doi: 10.1002/ hep.26663.
  49. Shipulin VP. [Nonalcoholic steatohepatitis]. Ukr. Med. J. 2007;9:27-32.
  50. Siedlecka J, Gadzicka E, Szyjkowska A, Siedlecki P, Szymczak W, Makowiec Dąbrowska T, Bortkiewicz A. [Prevention of cardiovascular diseases - Prophylactic program in a selected enterprise]. Med Pr. 2017 Sep 18. pii: 70529. doi: 10.13075/mp.5893.00548.
  51. Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity (Silver Spring). 2017;25(8):1313-1316. doi: 10.1002/oby.21879.
  52. Stanek A, Cholewka A, Wielkoszyński T, Romuk E, Sieroń K, Sieroń A. Increased Levels of Oxidative Stress Markers, Soluble CD40 Ligand, and Carotid Intima-Media Thickness Reflect Acceleration of Atherosclerosis in Male Patients with Ankylosing Spondylitis in Active Phase and without the Classical Cardiovascular Risk Factors. Oxid Med Cell Longev. 2017;2017:9712536. doi: 10.1155/2017/9712536. 
  53. Suzuki T, Katz R, Jenny NS, et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ Heart Fail. 2008;1(4):242–8.
  54. Tabit CE, Chung WB, Hamburg NM, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010;11(1):61–74.
  55. Targher G. Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29(6):1325–1330.
  56. Teague HL, Ahlman MA, Alavi A, Wagner DD, Lichtman AH, Nahrendorf M, Swirski FK, Nestle F, Gelfand JM, Kaplan MJ, Grinspoon S, Ridker PM, Newby DE, Tawakol A, Fayad ZA, Mehta NN. Unraveling Vascular Inflammation: From Immunology to Imaging. J Am Coll Cardiol. 2017 Sep 12;70(11):1403–1412. doi: 10.1016/j.jacc.2017.07.750.
  57. Thakur ML, Sharma S, Kumar A et al. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians. Atherosclerosis. 2012;223:507–511.
  58. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart. 2007;93(8):1001–7.
  59. Tu WJ, Liu Q, Cao JL, Zhao SJ, Zeng XW, Deng AJ. γ-Glutamyl Transferase as a Risk Factor for All-Cause or Cardiovascular Disease Mortality Among 5912 Ischemic Stroke. Stroke. 2017 Sep 13. pii: STROKEAHA.117.017776. doi: 10.1161/STROKEAHA.117.017776.
  60. VanWagner LB, Wilcox JE, Colangelo LA, LloydJones DM, Carr JJ, Lima JA. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A populationbased study. Hepatology. 2015;62(3):773–783.
  61. Velichko VI, Kolotvina LI, Guriev AM. [Obesity and nonalcoholic fatty liver disease with cardiovascular risk positions in the practice of family doctor]. Health Transport of Ukraine. 2014;1:79–82.
  62. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causesn. American Journal of Epidemiology. 1995;142(7):699–708.
  63. Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, Burns R, Rayner M, Townsend N (2017). European Cardiovascular Disease Statistics 2017. European Heart Network, Brussels.
  64. Zvyagintseva TD, Chernobay AI. [Chronic diffuse liver diseases of a combined etiology: approaches to treatment from the perspective of evidence-based medicine]. Health of Ukraine. 2011;11-12:50-51.
  65. Titov VN. [The generality of atherosclerosis and inflammation: the specificity of atherosclerosis as an inflammatory process (hypothesis)]. Biochemistry. 2000;4:3–10.